Pharmaceutical

Zydus Lifesciences to launch Semaglutide Injection in I...

Company plans rollout under SEMAGLYN, MASHEMA and ALTERME brands with adjustabl...

Slate Medicines raises $130m in funds to progress anti-...

The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclon...

NorthX Biologics and Demeetra collaborate on GMP manufa...

The partnership brings together a high-titre glutamine synthetase (GS) knockout ...

B&R India hosts Innovations Day 2026 to showcase smart ...

Event highlights intelligent automation, industry collaboration, and next-gener...

Biocon receives US FDA approval for Liraglutide Injecti...

Approval covers 18 mg/3 mL prefilled pens for chronic weight management in the ...

Lupin receives US FDA approval for Brivaracetam Oral So...

Company initiates US launch following ANDA approval for bioequivalent to Brivia...

DGFT rationalises RoDTEP scheme, reduces benefits by 50...

Value caps under the scheme have also been reduced by 50 per cent wherever appl...

Kiran Mazumdar-Shaw awarded Honorary Fellowship of the ...

Biocon Group Chairperson recognised for contributions to biomedical science and...

FDA accepts Beren Therapeutics’ NDA for Niemann-Pick di...

This marks a key development in the potential approval of adrabetadex, which cou...

AbbVie announces $380m investment in North Chicago API ...

These facilities will integrate advanced manufacturing technologies and AI for s...

Alembic Pharmaceuticals receives USFDA approval for Efi...

Product is therapeutically equivalent to Jublia; company holds 234 USFDA ANDA a...

NIT Rourkela startup receives CDSCO approval for StopBl...

Institute spinout Miraqules MedSolutions secures regulatory clearance for techn...

FDA reversal on Moderna’s mRNA-1010 can transform the s...

GlobalData highlights that the FDA’s review of Moderna’s mRNA-1010, with a 05 A...

US and Japan present narrower path for Alzheimer’s drug...

Only two monoclonal antibodies approved in both markets with no small molecules...

Eris Lifesciences partners Natco Pharma to commercialis...

CDSCO approval enables planned March 2026 launch targeting Type 2 diabetes mana...

AstraZeneca’s Calquence plus venetoclax gains approval ...

The approval was granted by the US Food and Drug Administration (FDA) and follow...